Syncromune Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $100M

  • Investors
  • 1

Syncromune General Information

Description

Developer of intratumoral immunotherapy designed to treat metastatic solid tumor cancers. The company's immunotherapy utilizes intratumoral sync technology to synchronize the timing and location of tumor antigen release with the functional activation of immune cells, enabling patients to power a personalized autologous vaccine with their cancer antigens.

Contact Information

Website
www.syncromune.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2919 East Commercial Boulevard
  • Suite 200
  • Fort Lauderdale, FL 33308
  • United States
+1 (518)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 2919 East Commercial Boulevard
  • Suite 200
  • Fort Lauderdale, FL 33308
  • United States
+1 (518)

Syncromune Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syncromune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 16-Dec-2024 $100M Completed Generating Revenue
2. Early Stage VC (Series A) 06-Oct-2023 Completed Generating Revenue
1. Debt - General 10-Feb-2022 $10.2M $10.2M Completed Generating Revenue
To view Syncromune’s complete valuation and funding history, request access »

Syncromune Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1
Series A-2
Series A-3 4,375,543 $0.000010 $2.74 $2.74 1x $2.74 6.2%
Series A-4 9,629,243 $0.000010 $2.08 $2.08 1x $2.08 13.64%
To view Syncromune’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Syncromune Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

Syncromune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230404642-A1 Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients Pending 01-Jun-2022
AU-2023281615-A1 A method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients Pending 01-Jun-2022
EP-4532556-A2 A method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients Pending 01-Jun-2022 A61B18/02

Syncromune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syncromune Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Wasatch Equity Partners PE/Buyout Minority
To view Syncromune’s complete investors history, request access »

Ready to get started?

Request a free trial

Syncromune FAQs

  • When was Syncromune founded?

    Syncromune was founded in 2020.

  • Where is Syncromune headquartered?

    Syncromune is headquartered in Fort Lauderdale, FL.

  • What is the size of Syncromune?

    Syncromune has 25 total employees.

  • What industry is Syncromune in?

    Syncromune’s primary industry is Drug Discovery.

  • Is Syncromune a private or public company?

    Syncromune is a Private company.

  • What is the current valuation of Syncromune?

    The current valuation of Syncromune is .

  • What is Syncromune’s current revenue?

    The current revenue for Syncromune is .

  • How much funding has Syncromune raised over time?

    Syncromune has raised $130M.

  • Who are Syncromune’s investors?

    Wasatch Equity Partners has invested in Syncromune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »